Pharmafile Logo
Pharmafocus logo
Advanced Search

Dupixent

Showing 15 posts of 23 posts found.

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023
Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial

Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …

News

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023
Medical Communications Dupixent, Ear Nose & throat, FDA, Regeneron, Sanofi

Regeneron Pharmaceuticals and Sanofi have announced that the US Food and Drug Administration (FDA) has accepted their supplemental Biologics License …

News
4420456374_64a3d7e6aa

Top Ten most popular articles on Pharmafile.com this week

December 4, 2020
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing COVID-19, Dupixent, EMA, UK, Vaccine, top ten

As the year winds to a close, excitement is rising around the efficacy and availability of COVID-19 vaccines around the …

News

Dupixent becomes first systemic medicine approved in Europe for children with severe atopic dermatitis

November 30, 2020
Sales and Marketing Dupixent, EU, Europe, Sanofi

The European Commission has moved to expand the existing authorisation of Sanofi and Regeneron’s Dupixent (dupilumab) in the European Union …

News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent shows strength at Phase 3 in eosinophilic esophagitis

October 27, 2020
Manufacturing and Production Dupixent, Sanofi, pharma

Sanofi has lifted the curtain on new Phase 3 data for Dupixent (dupilumab), showing that the drug met all of …

News
sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020
Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …

News
sanofi_hq__boetie_hall_web

Extension study reveals Dupixent’s benefit can last up to three years in moderate-to-severe asthma

September 8, 2020
Manufacturing and Production, Research and Development Dupixent, Sanofi, asthma, pharma

New findings have been revealed from an extension study of Sanofi’s interleukin-4 (IL-4) and interleukin-13 (IL-13) inhibitor Dupixent (dupilumab) in …

News
sanofi

Sanofi’s Dupixent scores Chinese approval in moderate to severe atopic dermatitis

June 22, 2020
Sales and Marketing China, Dupixent, Sanofi, atopic dermatitis, pharma

China’s National Medical Products Administration (NMPA) has moved to approve a 300mg pre-filled pen formulation of Sanofi and Regeneron’s Dupixent …

News
fda

FDA approves Sanofi’s Dupixent for children with dermatitis

May 27, 2020
Research and Development Dupixent, Sanofi, atopic eczema

The FDA has approved Sanofi’s Dupixent (dupilumab) for children between ages 6 to 11 with moderate to severe atopic dermatitis. …

News

Sanofi and Regeneron’s Dupixent combo impresses in paediatric atopic dermatitis

April 3, 2020
Medical Communications, Research and Development Dupixent, Sanofi, atopic dermatitis, pharma

Sanofi and Regeneron have unveiled new Phase 3 data for their IL-4 and IL-13 inhibitor Dupixent (dupilumab), showing strong results …

News
nice_new_london_office_internal_3_web

NICE shoots down Dupixent for severe asthma

March 9, 2020
Sales and Marketing Dupixent, NHS, NICE, Regeneron, Sanofi, UK, asthma

NICE, the NHS’ drug watchdog in England and Wales, has announced its decision not to recommend Sanofi and Regeneron’s IL-4 …

News

European Commission approves Sanofi’s Dupixent in chronic rhinosinusitis with nasal polyposis

October 30, 2019
Research and Development, Sales and Marketing Dupixent, EU, Sanofi, pharma

Sanofi’s Dupixent (dupilumab) has secured European approval for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP), it has emerged. …

News
dupixentpackage

Sanofi’s Dupixent improves skin clearance in paediatric atopic dermatitis

August 7, 2019
Research and Development Dupixent, Sanofi, atopic dermatitis, pharma

As the therapy secured approval in Europe for treatment of adolescent patients with moderate-to-severe atopic dermatitis, Sanofi has revealed new …

News
dw-anzcxqaqavhl

FDA approves Dupixent for chronic rhinosinusitis with nasal polyposis

June 27, 2019
Sales and Marketing Dupixent, FDA, Sanofi, US, pharma, rhinosinusitis

Regeneron Pharmaceuticals and Sanofi have revealed that their dual IL-4 and IL-13 inhibitor Dupixent (dupilumab) has secured FDA approval in …

News
dupixentpackage

Sanofi’s Dupixent approved in Europe for severe asthma maintenance

May 9, 2019
Sales and Marketing Dupixent, EU, Europe, Sanofi, asthma, pharma

Sanofi has revealed that its interleukin-4 and interleukin-13 (IL-4 and IL-13) inhibitor Dupixent (dupilumab) has been awarded marketing approval by …

News

Latest content

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023

Teva Pharmaceuticals shares phase 3 data for Ajovy as migraine treatment

December 6, 2023

British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing

December 5, 2023

Genentech shares positive results from phase 3 trial for breast cancer treatment

December 5, 2023

Dr Stefano Gulià appointed as chief scientific officer of Kling Bio

December 5, 2023